company background image
SLNC.F logo

Silence Therapeutics OTCPK:SLNC.F Stock Report

Last Price

US$3.25

Market Cap

US$945.9m

7D

30.0%

1Y

n/a

Updated

21 Feb, 2024

Data

Company Financials +

Silence Therapeutics plc

OTCPK:SLNC.F Stock Report

Market Cap: US$945.9m

SLNC.F Stock Overview

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications.

SLNC.F fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Silence Therapeutics plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Silence Therapeutics
Historical stock prices
Current Share PriceUS$3.25
52 Week HighUS$3.25
52 Week LowUS$0.60
Beta1.42
1 Month Change116.67%
3 Month Changen/a
1 Year Changen/a
3 Year Change-61.90%
5 Year Change405.84%
Change since IPO146.21%

Recent News & Updates

Recent updates

Shareholder Returns

SLNC.FUS BiotechsUS Market
7D30.0%0.6%-0.5%
1Yn/a5.8%22.3%

Return vs Industry: Insufficient data to determine how SLNC.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how SLNC.F performed against the US Market.

Price Volatility

Is SLNC.F's price volatile compared to industry and market?
SLNC.F volatility
SLNC.F Average Weekly Movementn/a
Biotechs Industry Average Movement11.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: SLNC.F's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine SLNC.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1994122Craig Toomanhttps://www.silence-therapeutics.com

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company’s mRNAi GOLD GalNAc Oligonucleotide Discovery platform that is used to target specific disease-associated genes in the liver. Its siRNA molecules to harness the body’s natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell.

Silence Therapeutics plc Fundamentals Summary

How do Silence Therapeutics's earnings and revenue compare to its market cap?
SLNC.F fundamental statistics
Market capUS$945.87m
Earnings (TTM)-US$53.80m
Revenue (TTM)US$35.40m

26.7x

P/S Ratio

-17.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SLNC.F income statement (TTM)
RevenueUK£28.04m
Cost of RevenueUK£12.83m
Gross ProfitUK£15.21m
Other ExpensesUK£57.83m
Earnings-UK£42.62m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.10
Gross Margin54.24%
Net Profit Margin-151.98%
Debt/Equity Ratio0%

How did SLNC.F perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.